Quarterly ResultAug 11, 2026, 04:14 PM
Taysha Gene Therapies Q2 Net Loss $46.6M; Cash Runway into 2H 2028
AI Summary
Taysha Gene Therapies reported a net loss of $46.6 million for Q2 2026, with increased R&D and G&A expenses. The company announced significant progress in its TSHA-102 program for Rett syndrome, completing dosing in both the REVEAL pivotal and ASPIRE trials, with TSHA-102 continuing to be well-tolerated. A $230 million follow-on offering strengthened its balance sheet, extending the cash runway into the second half of 2028 and through potential BLA approval.
Key Highlights
- Net loss for Q2 2026 was $46.6 million, compared to $26.9 million in Q2 2025.
- Research and development expenses increased to $38.6 million from $20.1 million year-over-year.
- General and administrative expenses rose to $12.1 million from $8.6 million year-over-year.
- Completed a $230 million follow-on offering, including the underwriters' option.
- Cash and cash equivalents totaled $455.4 million as of June 30, 2026.
- Cash runway extended into 2H 2028, covering potential BLA approval of TSHA-102.
- Completed dosing in the REVEAL pivotal (N=17) and ASPIRE (N=4) trials for TSHA-102.
- TSHA-102 continues to be generally well-tolerated across all trials (N=33) with no severe treatment-related SAEs or DLTs.
- Expects topline data from REVEAL 6-month interim analysis and FDA feedback on BLA pathway in 1H 2027.
Price Impact
More from TSHA